[General aspects of cytostatic therapy of hemoblastoses].
In haemoblastoses the chemotherapy is able to achieve remissions and prolongations of the survival time. The combined or polychemotherapy, respectively, is here comparatively more effective than the monotherapy. In haemoblastoses the concept of the maximal destruction of tumours (induction therapy) could be realised by means of consolidation and maintenance therapy. The prediction of the therapy effects by inclusion of different host parameters (morphology, immune state, age, sensibility test) may only approximately be done. In the induction and maintenance of the remission the supportive therapeutic measures play an essential role. By the development of selective cytostatic drugs and further utilisation of the results of molecular-biological experiments further ameliorations of the therapeutic situation are to be awaited.
D000477:Alkylating Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D000970:Antineoplastic Agents; D014750:Vincristine; D014747:Vinblastine; D001215:Asparaginase
Allgemeine Aspekte der zytostatischen Therapie der HAmoblastosen